WS Investor
01 Sep 2026, 14:54
Medtronic Invests $700 Million in Cornerstone Robotics to Expand Surgical Robot Portfolio
Medtronic (NYSE: MDT) announced Tuesday a strategic partnership with Cornerstone Robotics, investing approximately $700 million to expand its presence in the rapidly growing robotic-assisted surgery market.
The agreement gives Medtronic rights to distribute Cornerstone’s Sentire surgical system in select markets outside the U.S. where the platform has regulatory approval. Medtronic plans to offer Sentire alongside its existing Hugo robotic-assisted surgery system, creating a two-platform portfolio aimed at different clinical, operational and economic requirements.
Sentire received CE Mark in May 2026 for minimally invasive general, gynecologic, thoracic and urologic procedures and is also approved in China and Singapore. The system features an immersive console and dual-console capability.
The investment strengthens one of Medtronic’s key long-term growth opportunities. Global penetration of robotic-assisted surgery remains in the single digits, leaving substantial room for hospitals to transition from conventional procedures toward robotic systems.
Medtronic also highlighted accelerating adoption of Hugo, which is now used in more than 35 countries across six continents and received U.S. FDA clearance within the past year. Hugo procedure volumes are currently growing at more than twice the overall robotic surgery market rate, with cumulative procedures expected to exceed 50,000 globally by the end of Medtronic’s fiscal year.
The Cornerstone partnership gives Medtronic a broader offering as it competes in a surgical robotics market dominated by Intuitive Surgical. Combined with continued investment in Hugo, AI, digital surgery, integrated stapling and new instruments, the Sentire deal could strengthen Medtronic’s ability to capture a larger share of the expanding global robotic surgery market.
Medtronic (NYSE: MDT) announced Tuesday a strategic partnership with Cornerstone Robotics, investing approximately $700 million to expand its presence in the rapidly growing robotic-assisted surgery market.
The agreement gives Medtronic rights to distribute Cornerstone’s Sentire surgical system in select markets outside the U.S. where the platform has regulatory approval. Medtronic plans to offer Sentire alongside its existing Hugo robotic-assisted surgery system, creating a two-platform portfolio aimed at different clinical, operational and economic requirements.
Sentire received CE Mark in May 2026 for minimally invasive general, gynecologic, thoracic and urologic procedures and is also approved in China and Singapore. The system features an immersive console and dual-console capability.
The investment strengthens one of Medtronic’s key long-term growth opportunities. Global penetration of robotic-assisted surgery remains in the single digits, leaving substantial room for hospitals to transition from conventional procedures toward robotic systems.
Medtronic also highlighted accelerating adoption of Hugo, which is now used in more than 35 countries across six continents and received U.S. FDA clearance within the past year. Hugo procedure volumes are currently growing at more than twice the overall robotic surgery market rate, with cumulative procedures expected to exceed 50,000 globally by the end of Medtronic’s fiscal year.
The Cornerstone partnership gives Medtronic a broader offering as it competes in a surgical robotics market dominated by Intuitive Surgical. Combined with continued investment in Hugo, AI, digital surgery, integrated stapling and new instruments, the Sentire deal could strengthen Medtronic’s ability to capture a larger share of the expanding global robotic surgery market.
